tenofovir has been researched along with epoxyfarnesyl diazoacetate in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 3 (30.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amano, M; Anderson, KS; Bailey, CM; Cheng, YC; Hayakawa, H; Kodama, E; Koh, Y; Kohgo, S; Matsuoka, M; Mitsuya, H; Nakata, H; Yang, G | 1 |
| Didier, PJ; Michael, H; Mitsuya, H; Murphey-Corb, M; Nyaundi, J; Parniak, MA; Rajakumar, P; Reeve, AB; Sarafianos, SG | 1 |
| Hachiya, A; Huber, AD; Jackson, JC; Kirby, KA; Kodama, EN; Leslie, MD; Marchand, B; Michailidis, E; Mitsuya, H; Ong, YT; Parniak, MA; Ryan, EM; Sarafianos, SG; Singh, K | 1 |
| Aoki, M; Desai, DV; Kodama, EN; Maeda, K; Mitsuya, H; Nakata, H | 1 |
| Jones, J; Taylor, BS; Tieu, HV; Wilkin, TJ | 1 |
| Aralaguppe, SG; Neogi, U; Njenda, DT; Rao, R; Sarafianos, SG; Singh, K; Sönnerborg, A | 1 |
| Coelho, LE; Grinsztejn, B; Landovitz, RJ; Torres, TS; Veloso, VG | 1 |
| Armas, D; Fillgrove, KL; Fox-Bosetti, S; Friedman, E; Iwamoto, M; Matthews, RP; Rudd, DJ; Stoch, SA; Zhang, S | 1 |
| Afani Saud, A; Bettacchi, C; Chahin Anania, C; Correll, T; Eves, K; Grandhi, A; Hanna, GJ; Hepler, D; Hwang, C; Klopfer, SO; Molina, JM; Robertson, MN; Yazdanpanah, Y | 1 |
| Carrillo, CM; Cilento, ME; Edwards, K; Kitzler, DR; Kodama, EN; Mitsuya, H; Parniak, MA; Reeve, AB; Sarafianos, SG; Smith, CP; Snyder, AA; Tedbury, PR; Ukah, OB; Wahoski, CC; Wen, X | 1 |
1 review(s) available for tenofovir and epoxyfarnesyl diazoacetate
| Article | Year |
|---|---|
Pre-exposure prophylaxis 2.0: new drugs and technologies in the pipeline.
Topics: Adenine; Administration, Cutaneous; Administration, Oral; Alanine; Contraceptive Devices, Female; Delayed-Action Preparations; Deoxyadenosines; Emtricitabine; Female; HIV Infections; Humans; Incidence; Male; Medication Adherence; Pre-Exposure Prophylaxis; Tenofovir | 2019 |
2 trial(s) available for tenofovir and epoxyfarnesyl diazoacetate
| Article | Year |
|---|---|
Lack of a Clinically Meaningful Drug Interaction Between the HIV-1 Antiretroviral Agents Islatravir, Dolutegravir, and Tenofovir Disoproxil Fumarate.
Topics: Adult; Anti-Retroviral Agents; Deoxyadenosines; Drug Interactions; Heterocyclic Compounds, 3-Ring; HIV-1; Humans; Oxazines; Piperazines; Pyridones; Tenofovir | 2021 |
Brief Report: Efficacy and Safety of Oral Islatravir Once Daily in Combination With Doravirine Through 96 Weeks for Treatment-Naive Adults With HIV-1 Infection Receiving Initial Treatment With Islatravir, Doravirine, and Lamivudine.
Topics: Adult; Anti-HIV Agents; Deoxyadenosines; Drug Combinations; HIV Infections; HIV-1; Humans; Lamivudine; Pyridones; Reverse Transcriptase Inhibitors; RNA; Tenofovir; Triazoles | 2022 |
7 other study(ies) available for tenofovir and epoxyfarnesyl diazoacetate
| Article | Year |
|---|---|
Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4'-ethynyl-2-fluoro-2'-deoxyadenosine.
Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; Cells, Cultured; Culture Media; Deoxyadenosines; DNA-Directed DNA Polymerase; HIV-1; Humans; Microbial Sensitivity Tests; Reverse Transcriptase Inhibitors; Tritium; Zidovudine | 2007 |
Response of simian immunodeficiency virus to the novel nucleoside reverse transcriptase inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine in vitro and in vivo.
Topics: Adenine; Animals; Antiviral Agents; Cells, Cultured; Deoxyadenosines; Deoxycytidine; Emtricitabine; Leukocytes, Mononuclear; Macaca mulatta; Male; Mutation; Organophosphonates; Recurrence; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Tenofovir; Viral Load; Zidovudine | 2012 |
Hypersusceptibility mechanism of Tenofovir-resistant HIV to EFdA.
Topics: Adenine; Anti-HIV Agents; Cell Line; Deoxyadenosines; Drug Resistance, Viral; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Mutant Proteins; Mutation, Missense; Organophosphonates; Tenofovir | 2013 |
Delayed emergence of HIV-1 variants resistant to 4'-ethynyl-2-fluoro-2'-deoxyadenosine: comparative sequential passage study with lamivudine, tenofovir, emtricitabine and BMS-986001.
Topics: Adenine; Amino Acid Sequence; Anti-HIV Agents; Deoxyadenosines; Deoxycytidine; Drug Resistance, Multiple, Viral; Emtricitabine; HIV Infections; HIV-1; Human Immunodeficiency Virus Proteins; Humans; Lamivudine; Molecular Sequence Data; Molecular Structure; Organophosphonates; Tenofovir; Thymidine | 2014 |
CROI 2018: Advances in Antiretroviral Therapy.
Topics: Adenine; Amides; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Congresses as Topic; Deoxyadenosines; Drug Therapy, Combination; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Piperazines; Pyridones; Tenofovir; Viral Load | 2018 |
Antiretroviral potency of 4'-ethnyl-2'-fluoro-2'-deoxyadenosine, tenofovir alafenamide and second-generation NNRTIs across diverse HIV-1 subtypes.
Topics: Adenine; Alanine; Anti-Retroviral Agents; Deoxyadenosines; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Recombination, Genetic; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure | 2018 |
HIV-1 Resistance to Islatravir/Tenofovir Combination Therapy in Wild-Type or NRTI-Resistant Strains of Diverse HIV-1 Subtypes.
Topics: Anti-HIV Agents; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Mutation; Reverse Transcriptase Inhibitors; Tenofovir | 2023 |